Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphoid 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 3Vincristine 2Methotrexate 2tozasertib 1thymoglobulin 1romiplostim 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1lucatumumab 1fludarabine 1fenebrutinib 1enzastaurin 1duvelisib 1Receptors, Chimeric Antigen 1Prednisone 1Prednisolone 1Hydrocortisone 1Hu-Mik-beta-1 monoclonal antibody 1Doxorubicin 1Dasatinib 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphoid × fenebrutinib × Clear all
NCT01991184 2022-06-21

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Genentech, Inc.

Phase 1 Completed
24 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡